Products & Services · Total revenues
Roche Development Services Obligation — Total revenues
Alnylam Pharmaceuticals Roche Development Services Obligation — Total revenues increased by 9.9% to $34.41M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 117.2%, from $15.84M to $34.41M. Over 2 years (FY 2023 to FY 2025), Roche Development Services Obligation — Total revenues shows an upward trend with a 92.7% CAGR.
Analysis
Metric ID:
alny_segment_roche_development_services_obligation_total_revenuesHistorical Data
13 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $200K | $23.77M | $7.15M | $12.8M | $14.88M | $10.92M | $15.84M | $16.69M | $25.17M | $31.31M | $34.41M |
| QoQ Change | — | — | — | >999% | -69.9% | +79.0% | +16.3% | -26.6% | +45.0% | +5.4% | +50.8% | +24.4% | +9.9% |
| YoY Change | — | — | — | — | — | — | >999% | -54.1% | +121.5% | +30.4% | +69.1% | +186.6% | +117.2% |
Range$0 – $34.41M
Avg YoY Growth>999%
Median YoY Growth+117.2%
Current Streak5 quarters growth
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's roche development services obligation — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported roche development services obligation — total revenues of $34.41M in Q1 2026.
- How has Alnylam Pharmaceuticals's roche development services obligation — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's roche development services obligation — total revenues increased by 117.2% year-over-year, from $15.84M to $34.41M.
- What is the long-term trend for Alnylam Pharmaceuticals's roche development services obligation — total revenues?
- Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's roche development services obligation — total revenues has grown at a 92.7% compound annual growth rate (CAGR), from $23.97M to $89M.